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Buruli ulcer (BU) is a disabling and stigmatising neglected tropical disease (NTD). Its distribution and 17 
burden are unknown because of underdiagnosis and underreporting. It is caused by Mycobacterium 18 
ulcerans, an environmental pathogen whose environmental niche and transmission routes are not 19 
fully understood. Active BU case searches can limit morbidity by identifying cases and linking them 20 
to treatment, but these are mostly restricted to well-known endemic areas. A better understanding 21 
of environmental suitability for environmental reservoirs of M. ulcerans and BU disease would 22 
advance understanding of the disease’s ecology and burden, and could inform targeted surveillance.  23 
Methodology/Principal Findings 24 
We used previously compiled point-level datasets of BU and M. ulcerans occurrence, evidence for 25 
BU occurrence within national and sub-national areas, and diverse environmental datasets. We 26 
fitted relationships between BU and M. ulcerans occurrence and environmental predictors by 27 
applying regression and machine learning based algorithms, combined in an ensemble model to 28 
characterise the optimal ecological niche for the disease and bacterium across Africa at a resolution 29 
of 5km x 5km. Climate and atmospheric variables were the strongest predictors of both 30 
distributions, while indicators of human disturbance including damming and deforestation, drove 31 
local variation in suitability. We identified patchy foci of suitability throughout West and Central 32 
Africa, including areas with no previous evidence of the disease. Predicted suitability for M. ulcerans 33 
was wider but overlapping with that of BU. The estimated population living in areas predicted 34 
suitable for the bacterium and disease was 29.1 million. 35 
Conclusions/Significance 36 
These maps could be used to inform burden estimations and case searches which would generate a 37 
more complete understanding of the spatial distribution of BU in Africa, and may guide control 38 
programmes to identify cases beyond the well-known endemic areas. 39 
 40 
 41 
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Author summary 43 
Like many neglected tropical diseases primarily affecting the rural poor, Buruli ulcer (BU) is under-44 
detected and under-reported within routine health information systems. As such, the burden and 45 
distribution are not fully known, impeding appropriate targeting of health resources, control, and 46 
care for people affected. Having previously evaluated and mapped the existing evidence for BU and 47 
its causative agent M. ulcerans, we concluded that the disease was likely to occur beyond the range 48 
of known endemic areas. However, we were left with the question of where exactly these 49 
undetected cases might be occurring. Answering this question required a more fine-scale approach: 50 
BU is highly focal, presumably due to local variation in the environmental factors which determine 51 
suitability for M. ulcerans survival and transmission to humans. We used the compiled evidence and 52 
geographical datasets to build statistical models representing the relationship between 53 
environmental factors and previously reported cases. This allowed us to define the ecological niche 54 
of BU, and subsequently to identify areas across Africa where this niche was met, providing suitable 55 
conditions for the disease. We constructed separate models of suitability for M. ulcerans, using 56 
locations where its DNA had been detected in environmental sources. Unsurprisingly, suitability for 57 
M. ulcerans was predicted to be wider than, but geographically overlapping with that for BU. This 58 
implies that beyond the conditions necessary for survival of the bacterium, additional factors are 59 
required for transmission to humans. The high-resolution suitability maps we present are intended 60 
to guide case search activities which may identify endemic areas beyond the known endemic range. 61 
Data on the true prevalence of BU from targeted case searches within predicted-suitable areas will 62 
also allow us to validate and refine the models, and potentially predict the actual probability of cases 63 
occurring within predicted suitable areas.  64 
 65 
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Buruli ulcer (BU) is a chronic necrotizing disease of the skin and soft tissue, which causes debilitating 68 
symptoms and sequelae, associated with a high burden of morbidity and stigma for patients and 69 
economic costs for affected households [1-3]. These impacts are felt particularly strongly in 70 
impoverished rural communities with poor access to health services [3, 4]. The infectious agent is 71 
Mycobacterium ulcerans, a slow-growing environmental bacterium which may be transmitted from 72 
aquatic environments to humans via inhalation or ingestion, or by penetration of the skin [1, 5, 6]. 73 
The main control strategy is active case finding in endemic areas to promote early case detection 74 
and effective treatment, which limits disease progression [7, 8]. BU occurs mostly in tropical and 75 
subtropical areas of West and Central Africa, with smaller foci in parts of Asia, South America, the 76 
Western Pacific and Australasia [9]. However, the disease is recognised to be underdiagnosed and 77 
under-reported, and may occur undetected in other parts of the world [9-12].  78 
The distribution of BU is presumably linked to environmental suitability for M. ulcerans survival and 79 
replication, as well as to human and environmental factors favouring transmission [13]. On a 80 
continental scale, BU appears to be limited by climatic factors: it is restricted to tropical and 81 
subtropical regions and absent from arid areas [14]. Within endemic areas, the disease shows a 82 
highly focal distribution [15-17], but reasons for this are not well understood, since the precise niche 83 
and transmission routes of M. ulcerans have been difficult to characterise [18]. The pathogen has 84 
only been cultured from environmental and animal samples a handful of times [19-21], although it 85 
has been detected by PCR in aquatic environments of endemic and non-endemic areas, and a in 86 
wide range of potential hosts including mammals, fish, amphibians, and aquatic and terrestrial 87 
insects [22-26]. Consistent with the ecology of an environmental pathogen, the distribution of M. 88 
ulcerans in the environment appears to be wider than that of BU, suggesting that factors beyond 89 
environmental suitability for M. ulcerans are required for transmission [13, 14, 27]. 90 
Our understanding of the pathways of BU infection is also limited, partly by its long and variable 91 
incubation period, which makes it difficult for patients and clinicians to attribute particular events or 92 
activities to disease acquisition [28]. Local spatial analysis has identified several environmental 93 
variables associated with increased BU incidence, primarily proximity to rivers, as well as 94 
environmental disturbance and land-use changes including deforestation, urbanisation, 95 
agriculturalization and mining [17, 29]. Case control studies have identified contact with unprotected 96 
waterbodies as a risk factor for disease [30], suggesting that activities which bring people into 97 
contact with water sources harbouring M. ulcerans increase the risk of disease acquisition [31-33]. 98 
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Given the recognised scale of BU under-detection and under-reporting, it is likely that BU occurs 99 
beyond the known range of reported cases. A better understanding of potential suitability for the 100 
pathogen in the environment and the disease in humans would help to improve its surveillance and 101 
control in countries where is known to be endemic. Furthermore, characterisation of the 102 
environmental factors linked to suitability for M. ulcerans and BU may reveal areas at risk for disease 103 
emergence, or places harbouring unrecognised cases.  104 
In this investigation, we aim to identify environmental factors which characterise the environmental 105 
niche of M. ulcerans and BU disease in humans, and to model their respective relationships with BU. 106 
These analyses will be used to identify areas of continental Africa which may be suitable for M. 107 
ulcerans or BU based on their environmental characteristics.  108 
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Data on Buruli ulcer and M. ulcerans distribution 110 
We used previously compiled spatial datasets of point locations of recorded occurrences of BU 111 
disease in humans, and of detection of M. ulcerans genetic material in biotic and abiotic 112 
environmental samples [9, 34]. Data for the final models was extracted from the database on 113 
03/01/2020. 114 
BU occurrence locations were restricted to those where BU infection was confirmed by a positive 115 
result for PCR targeting IS2404, or histopathology consistent with BU disease. To explore the model’s 116 
sensitivity to the case definition, we repeated the analysis using all locations where clinically 117 
diagnosed BU had been reported. We hereon refer to the two datasets as ‘confirmed occurrences’ 118 
and ‘all occurrences’ respectively.  119 
The environmental dataset was restricted to locations where M. ulcerans DNA had been identified 120 
and distinguished from that of other mycobacteria: either by multiplex qPCR assays quantifying the 121 
relative copy numbers of IS2404, IS2606 and the KR-B domain [35]; byvariable nucleotide tandem 122 
repeat (VNTR); or mycobacterial interspersed repetitive unit (MIRU) typing [36, 37]. We hereon refer 123 
to this dataset as ‘environmental occurrences’.  124 
All records were restricted to locations with reliable geographical coordinates and deduplicated by 125 
geographical location. Human and environmental locations were weighted by the year and the 126 
specificity of confirmatory tests reported (S1 Text). 127 
Environmental datasets used in ecological modelling 128 
We assembled gridded datasets of 51 environmental variables considered relevant to the ecological 129 
niche of M. ulcerans [18]. All variables and their sources are shown in Table 1 and full details are 130 
provided in S3 Text. 131 
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Variable selection 133 
We compiled the gridded predictor variables at a resolution of 5km x 5km within a rectangular area 134 
of West Africa from latitude -13.57195, longitude-4.11032, to lat. 16.67107, long. 14.493. This area 135 
contained 94% of all BU occurrence locations, 95% of confirmed BU occurrence locations, and all 136 
environmental occurrence locations. We extracted the values of predictor variables at the locations 137 
of BU cases (all occurrences) and environmental occurrences of M. ulcerans DNA.  138 
We used principal components analysis (PCA) to identify the minimum set of variables that best 139 
characterized the environment at observations of BU and of M. ulcerans from the global 140 
environment. We undertook separate PCAs on the human (confirmed cases) and environmental 141 
datasets, selecting variables that contributed most strongly to the minimum number of principal 142 
components collectively accounting for at least 80% of the total dataset variance.  143 
Pseudoabsence and Background data  144 
The occurrence data used in the modelling framework were supplemented with systematically 145 
generated pseudo-absence and background data. The use of artificial absence data is a common 146 
approach in species distribution modelling, designed to account for geographically biased presence 147 
data and sparse absence data [38]. The terms background and pseudoabsence are often used 148 
interchangeably to describe artificial absence data, though Elith and Hijmans distinguish them on the 149 
basis that background data are intended to characterise the ‘environmental domain’ of the study- 150 
helping to account for geographical bias, while pseudoabsence data represent areas assumed to be 151 
unsuitable for the species and are intended to capture the environment in these areas [39]. We 152 
hereon use the terms in this sense.  153 
Pseudoabsence and background points were both selected from a restricted geographical extent 154 
around occurrence points, defined by the spatial structure of the occurrence predictors. This has 155 
been recommended by previous authors as way to provide an ecologically meaningful definition of 156 
the study range [40]. Pseudoabsence points were sampled at higher density in areas of weaker 157 
evidence according to a systematic review of the geographical distribution of BU [41]. Background 158 
points were sampled at higher density around recorded occurrence points. More details on the 159 
generation of pseudoabsence and background points are provided in S2 Text.  160 
Pseudoabsence and background weights were uniform within datasets and assigned so their sum 161 
was equal to the sum of occurrence weights in each model [42]. Human background points were 162 
restricted to a minimum distance of 10km from any occurrence location, and environmental 163 
background points were restricted to 10km from any human or environmental occurrence location. 164 
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The distribution of BU and M. ulcerans occurrences, pseudoabsence and background points are 165 
shown in S1 Figure and S2 Figure. 166 
Ensemble modelling 167 
The environmental factors selected through PCA were used as predictor variables. We used the 168 
biomod2 package in R [43, 44] to implement seven algorithms: generalized linear models (GLM), 169 
generalized additive models (GAM), generalized boosted regression models (GBM), artificial neural 170 
networks (ANN), multiple adaptive regression splines (MARS), maximum entropy (MaxEnt) and 171 
random forest (RF).  172 
Individual model algorithms were each run 20 times with a random sample of 80% of data points, 173 
and evaluated with the remaining 20%. For each algorithm we calculated the mean true skill statistic 174 
(TSS), the mean positive correctly classified (PCC) and the mean area under the curve (AUC) of the 175 
receiver operation characteristic (ROC) [45]. Models with mean AUC above 0.8 were integrated in an 176 
ensemble using committee averaging to attribute higher weight to better performing models. 177 
We plotted the importance values representing each variable’s contribution to the model and 178 
created marginal effect plots for the modelled covariates in the highest performing model ensemble.  179 
Estimating total population living in suitable areas 180 
We calculated the total area suitable for BU, M. ulcerans, and the total area suitable for both, and 181 
extracted estimates of the population living in each of these areas from a raster representing 182 
estimated number of people per 1km
2
 grid square in 2020 [46].   183 
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Datasets of BU occurrence in humans and M. ulcerans DNA detection in the environment 185 
The modelled data included 2,183 unique point locations with reported cases of BU in Africa (Figure 186 
1A). BU was confirmed by PCR or histopathology at 738 unique locations. There were 91 unique 187 
locations where M. ulcerans DNA had been detected by MIRU, VNTR or qPCR (Figure 1B). The 188 
dataset of clinically diagnosed human cases represented 16 countries, mostly in West and Central 189 
Africa, with a few in East and southeast Africa. The confirmed cases were restricted to 13 countries. 190 
The time period of human case detection was from 1957 to 2019. The median year of diagnosis was 191 
2010. The 91 records of environmental detection of M. ulcerans represented three countries: Ghana, 192 
Cameroon and Benin, and covered the period from 2006 to 2018 with a median year of detection of 193 
2013.  194 
Figure 1A: Selection of BU occurrence points from BU database 195 
Figure 1B: Selection of model environmental occurrence points from global database of MU 196 
occurrences 197 
Principal components analysis 198 
Ten principal components (PCs) collectively contributed 86% of variation in the human BU 199 
occurrence locations. Seven PCs characterised the environmental locations. The variables selected 200 
for each model are shown in S3 Text. The mean contribution of the most important predictors of 201 
human BU occurrence dropped sharply at 150km, while the contribution of the predictors of 202 
environmental detection of M. ulcerans declined at 300km (S4 Text). 203 
Environmental suitability for BU 204 
All individual distribution models performed well with ROC scores above 0.8 (S5 Text). Mean PCC 205 
scores were between 79.3 and 91.6% and mean TSS scores were between 0.57 and 0.79 (Figures A 206 
and B, S5 Text).RF performed best with a mean PCC of 91.6%, a mean TSS of 0.79 and mean ROC 207 
0.95. The final ensemble model showed an overall mean ROC of 0.96 with sensitivity of 87.1% and 208 
specificity of 92.9%. The mean TSS was 0.80 and the mean kappa score was 0.80 (Table 2).  209 
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Table 2: Validation metrics for ensemble models for BU and M. ulcerans suitability 211 
  
Weighted Mean Lower CI Upper CI 
BU 
suitability 
TSS 0.797 0.797 0.794 
ROC 0.963 0.961 0.963 
kappa 0.801 0.804 0.797 
    
MU 
suitability 
TSS 0.885 0.885 0.896 
ROC 0.96 0.96 0.961 
kappa 0.894 0.894 0.894 
 212 
The minimum temperature of the coldest month was the strongest contributor to the RF models, 213 
followed by PET and distance to dams (Figure A in S6 Text).Environments with minimum 214 
temperature below 18°C were unsuitable, but suitability increased sharply at this temperature, 215 
decreased a little from 20-21°C, before increasing again, remaining high up to 24°C (Figure A in S7 216 
Text). Optimal values of PET were between 1,000 and 1,500mm per month, corresponding to 217 
tropical rainforest canopy cover. There was a gradual decline in suitability for BU with increasing 218 
distance to the nearest dam up to a distance of 80km, after which suitability dropped rapidly.  219 
The overall distribution was constrained to humid tropical areas and local scale variation appeared 220 
to be driven by hydrological features and deforestation patterns (Figure 2). The total area predicted 221 
to be suitable for BU was 338,500 km2, and the total population living in areas predicted suitable was 222 
69.7 million (Table 3). Pockets of suitability for BU totalling >100 km
2
 were predicted in 16 countries 223 
in Africa, including all 12 countries along the west-central African coastline from Liberia to Angola 224 
(S2 Table). Angola had the widest area predicted suitable, followed by the Democratic Republic of 225 
the Congo, although the patches of suitability predicted in these countries were associated with high 226 
uncertainty. Nigeria had the largest population at risk, with 17.8 million predicted to be living in 227 
areas suitable for BU, followed by the Democratic Republic of the Congo where 10.8 million were 228 
predicted to be living in suitable areas (S2 Table). 229 
The model including all cases of BU (S3 Figure) gave similar results to the model including confirmed 230 
cases only. The Pearson coefficient of correlation between the two models was 0.86. 231 
Figure 2: Predicted environmental suitability for the occurrence of BU disease in humans and 232 
associated error of prediction. 233 
Environmental suitability for M. ulcerans  234 
All models performed well with ROC above 0.8, apart from MAXENT Phillips which was excluded 235 
from the ensemble model. Mean PCC varied from 0.80- 0.89 between models and mean TSS was 236 
between 0.54 and 0.77 (Figures C and D, S5 Text). RF outperformed other algorithms in predicting 237 
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the occurrence of M. ulcerans. The final ensemble model had a mean TSS score of 0.87, with a 238 
sensitivity of 92.3 and specificity of 94.5% (Table 2). The ROC sore was 0.99 and the kappa score was 239 
0.87.  240 
The minimum temperature of the coldest month was the strongest predictor of M. ulcerans 241 
occurrence in the RF models, accounting for 24.6% of all variance in the model (Figure B in S6 Text). 242 
Distance to deforested areas was also a strong predictor, accounting for 23.7% of the variance. 243 
Suitability was low at coldest month minimum temperatures below 18°C, and increased sharply to a 244 
peak at 25°C. There was a strong response to the distance to deforested areas, with high suitability 245 
at close range to deforested areas, decreasing sharply at 25km (Figure B in S6 Text).  246 
The overall distribution appeared to be restricted by suitability for minimum temperature and 247 
precipitation in the driest month, with local variation driven by deforestation (Figure 3). The total 248 
area predicted to be suitable for M. ulcerans was 833,975km2, and the total population living in 249 
areas predicted suitable was 71.2 million (Table 3). Pockets of suitability were predicted in 31 250 
countries (S2 Table). The DRC had the widest area predicted suitable (184,500 km2) followed by Côte 251 
d'Ivoire (120,600 km2).The highest population living in suitable areas was in Nigeria (26.7 million).  252 
Figure 3: Predicted environmental suitability for the occurrence of M. ulcerans in the environment 253 
and associated error of prediction. 254 
Overlap of suitability for BU and M. ulcerans  255 
The total area predicted to be suitable for both BU and M. ulcerans was 126,775 km2, with 29.1 256 
million people predicted to be living in areas at risk. There were notable differences in the extents of 257 
the areas predicted suitable for BU disease and environmental M. ulcerans (Figure 4). There were 258 
wide areas in Sierra Leone and Cote d’Ivoire predicted suitable for M. ulcerans but not for BU 259 
disease, which was restricted to smaller pockets within these countries. Suitability for M. ulcerans 260 
was also predicted outside the predicted range of BU across central Africa and along the north-west 261 
cost of Mozambique, eastern Tanzania and coastal Kenya. In contrast, there were large patches in 262 
Central Africa predicted suitable for BU but not suitable for M. ulcerans. Ghana followed by 263 
Cameroon had the widest area predicted suitable for both BU and M. ulcerans. The highest 264 
populations living in areas predicted suitable for both BU and M. ulcerans were in Nigeria and 265 
Ghana, with 11.4 and 8.0 million respectively at risk.  266 
Figure 4: Predicted overlap of environmental suitability for BU and of M. ulcerans occurrence. 267 
  268 
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Table 3: Total area predicted suitable and population in areas at risk for Buruli ulcer, M. ulcerans, 269 





) Lower bound  Upper bound 
Population in 
suitable areas  Lower bound  Upper bound 
BU 338,500   283,950  425,600   69,740,630  62,573,091   83,050,754  
MU 912,600   767,775   1,112,275   88,542,574  75,380,436   104,645,747  
BU & MU 126,775   94,800  177,700   29,124,902  22,597,071   39,371,153  
 271 
Suitability for BU and M. ulcerans is shown by country in S1 Supporting Maps.  272 
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We have used ecological niche modelling to identify environmental factors associated with the 274 
occurrence of Buruli ulcer and its causative agent M. ulcerans, and to predict environmental 275 
suitability for the disease and bacterium across continental Africa. Incorporating existing data on BU 276 
distribution and a geo-environmental definition of the range of occurrences, the resulting maps 277 
represent evidence-based predictions within a relevant spatial context.  278 
There was substantial overlap in the factors contributing to suitability for human cases and 279 
environmental occurrence. Both BU and M. ulcerans were constrained to particular bioclimatic 280 
zones by environmental predictors which varied over large areas, characterising the humid tropical 281 
realm where BU is endemic in Africa. Our finding that areas with minimum temperature less than 282 
18°C were unsuitable for BU supports evidence for a different epidemiology of the disease in Africa 283 
compared to endemic areas of temperate Australia and Japan [47]. Local-scale variation in factors 284 
including the distance to dams, deforestation and hydrology resulted in a patchy distribution of 285 
predicted suitability, consistent with our understanding of the epidemiology of BU, which is 286 
recognised to be highly focal in endemic settings [48].  287 
We identified pockets of suitability for BU in patchy foci throughout the known-endemic range of 288 
the disease, particularly in the tropical zones of countries around the Gulf of Guinea. Throughout 289 
this range, suitability was predicted in regions not previously recognised as endemic. For example, 290 
two foci of suitability were predicted in Equatorial Guinea, which had no evidence of cases reported 291 
in peer-reviewed literature. However, these two areas correspond to the origins of a number of 292 
cases diagnosed by an expert in BU between 1995 and 2005 [49, 50].  293 
Some locations in northern Cameroon with previous evidence of PCR confirmed BU were found to 294 
be unsuitable for the disease. This discordance may be due to the model’s failure to identify suitable 295 
environments in areas of lower BU incidence. However, given the great volume of surveillance data 296 
collected by the well-established BU control programme in Cameroon, some patients are likely to 297 
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have been diagnosed outside the region where they acquired the disease [51], and we consider it 298 
plausible that some regions where BU has been recorded are not actually suitable for transmission. 299 
The suitability maps provide a depiction of areas potentially at risk for BU beyond what is known 300 
from the distribution of reported cases, currently the basis for targeting of surveillance and control. 301 
Given the recognised scale of underreporting of BU [41], the current approach is likely to exclude 302 
cases outside of known disease foci, and we suggest that areas predicted suitable for BU could be 303 
considered as targets for case finding activities, with the aim of identifying unrecognised foci and 304 
patients not known to the health system. Based on the wide areas of suitability predicted by this 305 
work and existing evidence of under-reporting of BU [52], the south of Nigeria would be a key target 306 
for case finding activities. There were wide areas predicted suitable in the Republic of Congo, the 307 
DRC and Angola, although these predictions were associated with significant uncertainty, which 308 
should be considered in the design of any future surveys. Suitable areas of Equatorial Guinea with 309 
historical evidence of cases would also be targets for case finding, although in this case the predicted 310 
suitable areas are more restricted, potentially necessitating a more stratified approach. A 311 
comparable approach has been applied to target malaria elimination efforts to transmission 312 
hotspots predicted through geospatial risk mapping [53], employing environmental modelling to 313 
impute risk in the absence of full surveillance coverage.  314 
The model predictions could also be used to inform the design of cross-sectional surveys for BU, 315 
combining exhaustive case searches with environmental modelling to achieve robust estimates of 316 
prevalence. In a nationwide survey for podoconiosis in Cameroon, the selection of survey 317 
communities was stratified according predicted suitability for the disease based on a model trained 318 
mainly using data from Ethiopia [54]. This survey identified higher rates of podoconiosis in 319 
communities that were predicted suitable, implying a benefit in terms of the cost per case identified, 320 
compared to a survey employing random selection of survey communities.  321 
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The validation metrics we calculated demonstrate the ability of the models to predict BU and M. 322 
ulcerans occurrence with high accuracy. However, these measures do not indicate the models’ 323 
generalisability to areas beyond the range of known locations. Validation against external datasets 324 
would be required to assess this quality and is a target for future analysis. 325 
The scale of analysis (grid cells at 5km x 5km) may have limited our ability to quantify the effect of 326 
predictors varying over small geographical scales. For example, the relatively small contribution of 327 
distance to waterways on suitability for BU was a surprising result, given that proximity to and 328 
contact with rivers have been identified as risk factors for BU disease [13, 18]. However, the 329 
variation we were able to capture in this predictor was limited, since most of the land area in 330 
tropical and sub-tropical Africa is within 10km of a river or stream, and much is within 5km. A 331 
previous analysis of land use and landcover and BU presence at large spatial scales in Benin found no 332 
association of BU at community level with proximity to water bodies [55]. The scale of analysis may 333 
also have limited our ability to capture fine scale variation in environmental suitability for BU. Our 334 
models predicted large contiguous areas of suitability in some areas with suitable bioclimatic 335 
conditions and within close proximity to stable night lights and deforested areas. Such areas may be 336 
suitable in reality, but exhibit an uneven distribution of disease due to factors not included in our 337 
models. 338 
We have identified areas of high suitability for BU and M. ulcerans within known endemic-areas, and 339 
in areas not currently recognised as endemic, but with evidence of possible undiagnosed or 340 
misdiagnosed BU. The population at highest risk of BU is within areas where BU and M. ulcerans 341 
niches overlap, comprising almost 30 million people in 2020. The focal nature of BU distribution, the 342 
recognised scale of under-detection, and the impact of late diagnosis on disease severity strongly 343 
suggest a targeted approach to active case finding as a means to control this disease. The fine-scale, 344 
evidence-based predictions presented here could provide a tool to target such efforts, which will 345 
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help to increase the proportion of cases linked to treatment, and contribute further research to 346 
establish the burden and distribution of this devastating disease.  347 
 348 
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in BU database
5,627 locations with recorded 
cases
3,533 point locations with reliable 
geo-coordinates
1,336 locations with cases 
confirmed by PCR/histopathology
3,318 locations with clinically-
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738 unique locations2,183 unique locations
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